Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elena Hernan Sancho"'
Autor:
Carmel M McEniery, Joseph Cheriyan, Ian B Wilkinson, Holly Pavey, Paul J Cacciottolo, Michalis S Kostapanos, Elena Hernan Sancho, Fotini Kaloyirou, Evangelia Vamvaka, Joanna Helmy, Annette Hubsch
Publikováno v:
BMJ Open, Vol 11, Iss 4 (2021)
Introduction Elevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only evidence-based approach to reduce CV morbidity and mortality. Sec
Externí odkaz:
https://doaj.org/article/fa181613378b4c968830e7d4d351a22c
Autor:
Spoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, Edward Banham-Hall, Simon Bond, Elena Hernan-Sancho, Sam Norton, Joseph Cheriyan, Andrew Cope, James Galloway, Frances Hall, David Jayne, Ian B. Wilkinson
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Abstract Objectives To determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC). Trial design Randomised, parallel 3-arm (1:1:1 ratio), open-la
Externí odkaz:
https://doaj.org/article/63f09148f0724a55aa704f4a7b2674c0
Autor:
Michalis Kostapanos, Elena Hernan Sancho, Carmel M. McEniery, Joseph Cheriyan, Ian B. Wilkinson, Joanna Helmy, Fotini Kaloyirou, Holly Pavey, Evangelia Vamvaka, Paul J. Cacciottolo, Annette Hubsch
Publikováno v:
BMJ Open, Vol 11, Iss 4 (2021)
BMJ Open
BMJ Open
IntroductionElevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only evidence-based approach to reduce CV morbidity and mortality. Seco
Autor:
Joseph Cheriyan, Elena Hernan-Sancho, Frances Hall, Marie Fisk, James Galloway, Spoorthy Kulkarni, Michalis Kostapanos, Sam Norton, David Jayne, Edward Banham-Hall, Andrew P. Cope, Ian B. Wilkinson, Simon Bond
Publikováno v:
Trials
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Objectives To determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC). Trial design Randomised, parallel 3-arm (1:1:1 ratio), open-label, Phas
Autor:
Paul J. Cacciottolo, Joseph Cheriyan, Elena Hernan Sancho, Kaisa M. Mäki-Petäjä, Evangelia Vamvaka, Fotini Kaloyirou, Annette Hubsch, Joanna Helmy, Ian B. Wilkinson, Michalis Kostapanos, Holly Pavey
Publikováno v:
Journal of the American College of Cardiology. 77:159